Skip to main content
. 2020 Nov 8;13(11):373. doi: 10.3390/ph13110373

Figure 3.

Figure 3

Comparison of over survival and hazard ratios (HR) in clinical trials incorporating immunotherapy in the first line for patients with non-small cell lung cancer. The treatment arms without and with immunotherapy are compared in KEYNOTE-024, KEYNOTE-042, KEYNOTE-189, KEYNOTE-407, CHECKMATE-227, CHECKMATE 9LA, IMpower110, IMpower130, and IMpower150.